Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Exclusion Criteria

• •Subject is unable to take colchicine for gout flare prophylaxis.
• •Subject has a history or suspicion of kidney stones.
• •Subject has any gastrointestinal disorder that affects motility and/or absorption.
• •Subject had unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants.
• •Subject has Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator.
• •Subject has an estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period.
• •Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing.
• •Subject is unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.